April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intravitreal TNF-Alpha Inhibitors for Refractory Neovascular Age-Related Macular Degeneration: A Pilot Study from the Pan American Collaborative Retina Study (PACORES) Group
Author Affiliations & Notes
  • Erick Hernandez-Bogantes
    Vitreo-Retinal, Instituto de Cirugia Ocular, San Jose, Costa Rica
  • J. Fernando Arevalo
    Vitreo-Retinal, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • Caio V. Regatieri
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Jose A Roca
    Vitreo-Retinal, Clinica Ricardo Palma, Lima, Peru
  • Michel E. Farah
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Lihteh Wu
    Vitreo-Retinal, Instituto de Cirugia Ocular, San Jose, Costa Rica
  • Footnotes
    Commercial Relationships  Erick Hernandez-Bogantes, None; J. Fernando Arevalo, None; Caio V. Regatieri, None; Jose A Roca, None; Michel E. Farah, None; Lihteh Wu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1656. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erick Hernandez-Bogantes, J. Fernando Arevalo, Caio V. Regatieri, Jose A Roca, Michel E. Farah, Lihteh Wu; Intravitreal TNF-Alpha Inhibitors for Refractory Neovascular Age-Related Macular Degeneration: A Pilot Study from the Pan American Collaborative Retina Study (PACORES) Group. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1656. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the short term visual and anatomic outcomes following intravitreal injections of 2 different tissue necrosis factor (TNF) alpha inhibitors in eyes with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) refractory to anti-VEGF agents.

Methods: : A multicenter study of 20 eyes with refractory CNV that were injected with adalimumab (n=4 for 2 mg) or infliximab (n=8 for 1 mg; n=8 for 2 mg). The main outcome measures were the best corrected visual acuity (BCVA) and the central macular thickness (CMT) at 3 months of follow-up.

Results: : The mean log MAR BCVA changed from 1.04 ± 0.23 at baseline to 1.06 ± 0.51 at 3 months (p=0.9375) in the 1mg infliximab group; 0.94 ± 0.48 at baseline to 0.85 ± 0.43 in the 2 mg infliximab group (p=0.4375) and 1.58 ± 0.50 at baseline to 1.38 ± 0.43 in the adalimumab group (p=0.500). The mean CMT changed from 387 ± 54 µm at baseline to 342 ± 108 µm (p=0.2898) in the 1mg infliximab group; 301 ± 42 µm at baseline to 284 ± 73 µm (p=0.7548) in the 2 mg infliximab group and remained unchanged at 348 ± 106 µm (p=0.308) in the adalimumab group. Adverse events included uveitis in 37.5% (6/16) of eyes injected with infliximab.

Conclusions: : Intravitreal infliximab and adalimumab do not appear to benefit eyes with refractory CNV secondary to AMD. Intravitreal injections of infliximab may elicit a severe intraocular inflammatory reaction.

Keywords: choroid: neovascularization • age-related macular degeneration • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×